{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:31:09Z","timestamp":1793043069828,"version":"4.5.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The Hyperhidrosis Quality of Life Index (HidroQoL\u00a9) is a measure of quality of life (QoL) impacts in hyperhidrosis (HH).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We aimed to establish score banding systems for the HidroQoL total score for specific contexts representing different severity\/impact categories by using the Dermatology Life Quality Index (DLQI) and the Hyperhidrosis Disease Severity Scale (HDSS) as anchors, including data from 357 patients from a phase III clinical trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We used the HDSS, the established DLQI score bands and two single items (items 5 and 7) of the DLQI as anchors for the creation of banding systems for the HidroQoL. These anchors were chosen via consensus among an expert group according to relevance to patient experience. Due to the distribution of the HDSS and the single DLQI item 7, receiver operating characteristic curves were computed in order to create an optimal cut-off value of the HidroQoL total score. For the DLQI banding system and the single DLQI item 5, we created a banding system for the HidroQoL based on the distribution of their different categories.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A score of 30 and greater is proposed as the cut-off value for sweating that \u2018always interferes in daily activities\u2019, based on the HDSS as anchor. In terms of overall skin QoL effects, score bands of 0\u20136, 7\u201318, 19\u201325, 26\u201332 and 33\u201336 represent \u2018no effect\u2019, \u2018small effect\u2019, \u2018moderate effect\u2019, \u2018very large effect\u2019 and \u2018extremely large effect\u2019 on the patient\u2019s life, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this study, we propose different banding systems for four different contexts: skin-specific QoL (DLQI banding), HH severity (HDSS), working and studying (single DLQI item 7) and social and leisure activities (single DLQI item 5). These banding systems and cut-off values can be used in clinical research and practice to place the patients in different severity categories.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljad444","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T20:13:01Z","timestamp":1701202381000},"page":"519-526","source":"Crossref","is-referenced-by-count":7,"title":["What do Hyperhidrosis Quality of Life Index (HidroQoL\u00a9) scores mean? Transferring science into practice by establishing a score banding system"],"prefix":"10.1093","volume":"190","author":[{"given":"Theresa","family":"Donhauser","sequence":"first","affiliation":[{"name":"Institute of Social Medicine and Health Systems Research, Otto-von-Guericke University Magdeburg , Magdeburg , Germany"},{"name":"University of Regensburg , Regensburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1672-7549","authenticated-orcid":false,"given":"Michaela","family":"Gabes","sequence":"additional","affiliation":[{"name":"Institute of Social Medicine and Health Systems Research, Otto-von-Guericke University Magdeburg , Magdeburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebru","family":"\u00d6zkan","sequence":"additional","affiliation":[{"name":"Institute of Social Medicine and Health Systems Research, Otto-von-Guericke University Magdeburg , Magdeburg , Germany"},{"name":"University of Regensburg , Regensburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7361-727X","authenticated-orcid":false,"given":"Clarissa","family":"Masur","sequence":"additional","affiliation":[{"name":"Dr. August Wolff GmbH & Co. KG Arzneimittel , Bielefeld , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kamudoni","sequence":"additional","affiliation":[{"name":"Darmstadt , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Salek","sequence":"additional","affiliation":[{"name":"School of Life and Medical Sciences, University of Hertfordshire , UK"},{"name":"Institute of Medicines Development , Cardiff , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Abels","sequence":"additional","affiliation":[{"name":"Dr. August Wolff GmbH & Co. KG Arzneimittel , Bielefeld , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3805-8219","authenticated-orcid":false,"given":"Christian","family":"Apfelbacher","sequence":"additional","affiliation":[{"name":"Institute of Social Medicine and Health Systems Research, Otto-von-Guericke University Magdeburg , Magdeburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,28]]},"reference":[{"key":"2024090210042936600_ljad444-B1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.thorsurg.2016.06.002","article-title":"Pathophysiology of hyperhidrosis","volume":"26","author":"Schick","year":"2016","journal-title":"Thorac Surg Clin"},{"key":"2024090210042936600_ljad444-B2","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s00105-018-4265-8","article-title":"Hyperhidrose \u2013 \u00e4tiopathogenese, diagnostik, klinik und therapie","volume":"69","author":"Wohlrab","year":"2018","journal-title":"Der Hautarzt"},{"key":"2024090210042936600_ljad444-B3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.21037\/shc.2019.05.05","article-title":"Hyperhidrosis prevalence and its impact on population","volume":"3","author":"Hasimoto","year":"2019","journal-title":"Shanghai Chest"},{"key":"2024090210042936600_ljad444-B4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12955-017-0693-x","article-title":"The impact of hyperhidrosis on patients\u2019 daily life and quality of life: a qualitative investigation","volume":"15","author":"Kamudoni","year":"2017","journal-title":"Health Qual Life Outcomes"},{"key":"2024090210042936600_ljad444-B5","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s13555-022-00885-w","article-title":"Hyperhidrosis: a central nervous dysfunction of sweat secretion","volume":"13","author":"Wohlrab","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2024090210042936600_ljad444-B6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/09546634.2018.1506080","article-title":"Hyperhidrosis quality of life measures: review and patient perspective","volume":"30","author":"Wade","year":"2019","journal-title":"J Dermatol Treat"},{"key":"2024090210042936600_ljad444-B7","author":"Kamudoni"},{"key":"2024090210042936600_ljad444-B8","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s11136-014-0825-2","article-title":"The development and validation of a disease-specific quality of life measure in hyperhidrosis: the Hyperhidrosis Quality of Life Index (HidroQOL\u00a9)","volume":"24","author":"Kamudoni","year":"2015","journal-title":"Qual Life Res"},{"key":"2024090210042936600_ljad444-B9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/bjd.19300","article-title":"Hyperhidrosis Quality of Life Index (HidroQoL\u00a9): further validation and clinical application in patients with axillary hyperhidrosis using data from a phase III randomized controlled trial","volume":"184","author":"Gabes","year":"2020","journal-title":"Br J Dermatol"},{"key":"2024090210042936600_ljad444-B10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jclinepi.2006.03.012","article-title":"Boer MR de","volume":"60","author":"Terwee","year":"2007","journal-title":"J Clin Epidemiol"},{"key":"2024090210042936600_ljad444-B11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-981-10-8414-0_3","volume-title":"Living with Chronic Disease: Measuring Important Patient-Reported Outcomes","author":"Kamudoni","year":"2018"},{"key":"2024090210042936600_ljad444-B12","author":"National Institute for Health and Care Excellence"},{"key":"2024090210042936600_ljad444-B13","first-page":"229","article-title":"Safety and efficacy of topical formulations containing 0.5, 1 and 2% glycopyrronium bromide in patients with primary axillary hyperhidrosis: a randomized, double-blind, placebo-controlled study","volume":"182","author":"Masur","year":"2020","journal-title":"Br J Dermatol"},{"key":"2024090210042936600_ljad444-B14","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/bjd.19810","article-title":"A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial","volume":"185","author":"Abels","year":"2021","journal-title":"Br J Dermatol"},{"key":"2024090210042936600_ljad444-B15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s41687-023-00596-6","article-title":"Hyperhidrosis Quality of Life Index (HidroQoL): further validation by applying classical test theory and item response theory using data from a phase III clinical trial","volume":"7","author":"Donhauser","year":"2023","journal-title":"J Patient Rep Outcomes"},{"key":"2024090210042936600_ljad444-B16","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/bjd\/ljac010","article-title":"Burden of disease: assessing quality-of-life impacts in hyperhidrosis","volume":"188","author":"Gabes","year":"2023","journal-title":"Br J Dermatol"},{"key":"2024090210042936600_ljad444-B17","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00042728-200504000-00006","article-title":"Prospective open-label study of botulinum toxin type A in patients with axillary hyperhidrosis: effects on functional impairment and quality of life","volume":"31","author":"Solish","year":"2005","journal-title":"Dermatol Surg"},{"key":"2024090210042936600_ljad444-B18","first-page":"908","article-title":"A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee","volume":"33","author":"Solish","year":"2007","journal-title":"Dermatol Surg"},{"key":"2024090210042936600_ljad444-B19","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1590\/1806-9282.62.09.843","article-title":"Translation and validation of Hyperhidrosis Disease Severity Scale","volume":"62","author":"Varella","year":"2016","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"2024090210042936600_ljad444-B20","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u00a0\u2013 a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"2024090210042936600_ljad444-B21","first-page":"997","article-title":"The Dermatology Life Quality Index 1994\u20132007: a comprehensive review of validation data and clinical results","volume":"159","author":"Basra","year":"2008","journal-title":"Br J Dermatol"},{"key":"2024090210042936600_ljad444-B22","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","article-title":"Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes","volume":"61","author":"Revicki","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"2024090210042936600_ljad444-B23","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s13312-011-0055-4","article-title":"Receiver operating characteristic (ROC) curve for medical researchers","volume":"48","author":"Kumar","year":"2011","journal-title":"Indian Pediatr"},{"key":"2024090210042936600_ljad444-B24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"key":"2024090210042936600_ljad444-B25","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s11136-018-1798-3","article-title":"COSMIN guideline for systematic reviews of patient-reported outcome measures","volume":"27","author":"Prinsen","year":"2018","journal-title":"Qual Life Res"},{"key":"2024090210042936600_ljad444-B26","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","article-title":"Translating the science of quality of life into practice: What do Dermatology Life Quality Index scores mean?","volume":"125","author":"Hongbo","year":"2005","journal-title":"J Invest Dermatol"},{"issue":"16","key":"2024090210042936600_ljad444-B27","article-title":"Role of health-related quality of life measures in the routine care of people with multiple sclerosis","volume":"3","author":"Solari","year":"2005","journal-title":"Health Qual Life Outcomes"},{"key":"2024090210042936600_ljad444-B28","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1200\/JCO.2004.06.078","article-title":"Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial","volume":"22","author":"Velikova","year":"2004","journal-title":"J Clin Oncol"},{"key":"2024090210042936600_ljad444-B29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11136-017-1616-3","article-title":"Moving from significance to real-world meaning: methods for interpreting change in clinical outcome assessment scores","volume":"27","author":"Coon","year":"2018","journal-title":"Qual Life Res"},{"key":"2024090210042936600_ljad444-B30","author":"US Food and Drug Administration"},{"key":"2024090210042936600_ljad444-B31","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s41687-020-0181-7","article-title":"Development and validation of an interpretive guide for PROMIS scores","volume":"4","author":"Rothrock","year":"2020","journal-title":"J Patient Rep Outcomes"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljad444\/56349689\/ljad444.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/4\/519\/58993211\/ljad444.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/4\/519\/58993211\/ljad444.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T12:41:58Z","timestamp":1725280918000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/190\/4\/519\/7453387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,28]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,11,28]]},"published-print":{"date-parts":[[2024,3,15]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljad444","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2023,11,28]]}}}